ClinicalTrials.gg
RecruitingNCT05858385Updated Apr 30, 2024

Predictive Study on Acute Radiation Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients

An observational study in Nasopharyngeal Carcinoma by AJCC V8 Stage and Radiation Induced Mucositis, sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-30.

Sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
700
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Mucositis with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Mucositis · China.

Started
2022
the only one that year
Observational
2 of 10
2 open now
Registered
6th of 10
by date
Lead sponsor
1 of 10
Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Among the 10 studies in Mucositis with a site in China, this one is the only one that started in 2022, is one of 2 observational ones, and was the 6th registered.

Mucositis

265 studies on the registry are indexed under Mucositis; 34 are open to participants now.

Browse Mucositis studies →

Open to participants now

5 of the 10 studies in Mucositis with a site in China are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Mucositis with a site in China, or all of them as a file.
02

Study summary

Exploring effective risk prediction models for severe Radiation-Induced Oral Mucositis (RIOM/RTOM), providing a research basis for mitigating oral radiation toxicity, and effectively improving the sensitivity of dentists in predicting the risk of severe RIOM in locally advanced nasopharyngeal carcinoma patients.Based on precise radiotherapy, it is proposed to extract OAR using the contour of local oral areas. Explore more accurate RIOM dose-response relationships.Exploring a new type of fusion classifier, by complementing the information between each base classifier, helps to maximize the utilization of the information contained in different factors to build a more objective, reliable, and efficient multi criteria decision-making based risk prediction model for severe RIOM. It use predictive models to identify key risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive mode.

Read the detailed description

This study investigates the prediction and management of Radiation-Induced Oral Mucositis (RIOM/RTOM) in patients with locally advanced nasopharyngeal carcinoma undergoing radiotherapy. RIOM is a significant concern due to its impact on the quality of life for patients and its potential to disrupt radiotherapy courses, affecting local tumor control rates. We systematically analyzed multifaceted data, including dosimetric parameters, clinical factors, and oral variables, to develop a predictive model for severe RIOM. The effectiveness of key risk factors in mitigating the risk of severe RIOM was further validated to predict and potentially prevent severe RIOM.

03

Conditions studied

  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Radiation Induced Mucositis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Nasopharyngeal cancer patients diagnosed with tissue biopsy and no distant metastasis, who underwent RTOM observation and treatment throughout the radiotherapy period in the Department of Stomatology

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed as nasopharyngeal carcinoma through pathological tissue , AJCC 8th edition bed staging is I-Iva stage, with no distant
  • First time receiving radical radiation therapy and receiving RTOM observation and treatment throughout the entire process in the Department of Stomatology
  • Complete information on anti-tumor treatment materials
  • No oral mucosal diseases that have not been effectively controlled in the past or still require long-term medication treatment
  • Other diseases that do not affect the treatment of nasopharyngeal carcinoma

Exclusion criteria

Exclusion Criteria:

  • Failure to complete radiotherapy, or material release time delayed by more than two weeks compared to plan
  • There are other diseases that affect the examination and treatment of oral mucosal inflammation, such as restricted mouth opening, Schegren's syndrome, etc
  • Expected survival time less than 6 months
  • Cases where patients withdraw from clinical trials at any time and for any reason
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
700 participants (estimated)
Patient registry
No

Groups and cohorts

  • Development and Validation of severe RIOM prediction model

    This group aims to develop an artificial intelligence model using a retrospective cohort to predict severe RIOM in patients diagnosed with LA-NPC and evaluate risk factors for severe RIOM and further validate the effectiveness of this risk factor in reducing the risk of severe RIOM on risk factors for severe RIOM identified by the predictive model.The oral evaluation of all patients was conducted by the same senior dentist, who evaluated the oral mucosal radiation toxicity weekly at baseline (before RT) and after RT, and performed RIOM scores.RIOM is classified using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v5.0) .

    Other: Intervention based on key factors identified by the severe RIOM prediction model

Interventions

  • OtherIntervention based on key factors identified by the severe RIOM prediction model

    Intervention based on key factors identified by the severe RIOM prediction model

06

What researchers measure

Primary outcomes

  1. Incidence of severe RIOM

    According to the CTCAE V5.0 ,Grade 3 and Grade 4 is considered severe RTOM

    Time frame: during radiotherapy

Secondary outcomes

  1. Risk factors of severe RIOM

    Patient factors, disease factors, and treatment related factors

    Time frame: baseline (before radiotherapy)

Other outcomes

  1. Changes from oral dryness in RIOM patients

    According to the Clinical oral dryness score(CODS),A total of 10 features were used to obtain the total CODS. A high total score indicates increased oral dryness.

    Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy

  2. Changes from salivary PH compared to baseline in RIOM patients

    Evaluation of salivary PH using pH indicator paper

    Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy

  3. Changes from the pain in xerostomia combined with RIOM patients

    The evaluation of pain is based on the Numerical Rating Scale (NRS), with a numerical score of 0-10. A score of less than 5 is considered mild pain, a score of 5-7 is moderate pain, and a score of 8 or above is severe pain.

    Time frame: Baseline, the 10th, 20th and 30th days of radiotherapy

07

Study locations

1 of 1 sites recruiting
  • Yu Zeng
    Guangzhou, Guangdong 510000, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2022 (actual). Primary completion is estimated for Jun 2024, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 15, 2023
StartActual
Sep 22, 2022
Primary completionEst.
Jun 30, 2024
CompletionEst.
Dec 31, 2024
Last update
Apr 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05858385
Lead sponsor
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Responsible party
Sponsor
First posted
May 15, 2023
Start date
Sep 22, 2022
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Apr 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion